A Phase 2 Study to Evaluate the Safety Efficacy of Two Dose/Volume Levels of a Single Intrathecal Preoperative Administration of AYX1 Injection in Patients Undergoing Unilateral Total Knee Arthroplasty

Trial Profile

A Phase 2 Study to Evaluate the Safety Efficacy of Two Dose/Volume Levels of a Single Intrathecal Preoperative Administration of AYX1 Injection in Patients Undergoing Unilateral Total Knee Arthroplasty

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs AYX 1 (Primary)
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors Adynxx
  • Most Recent Events

    • 30 Sep 2016 Primary endpoint (Pain with walking during 15 meter walk test for AYX1 1100mg/10 mL dose) has not been met, according to results presented at the 16th World Congress on Pain.
    • 30 Sep 2016 Primary endpoint (Pain with walking during 15 meter walk test for AYX1 660mg/6 mL dose) has been met, according to results presented at the 16th World Congress on Pain.
    • 30 Sep 2016 Results of this study, presented at the 16th World Congress on Pain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top